Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of schizandrol A, schizandrin and schizandrol extract to prevention and treatment of senile dementia

A technology of schisandrin A and schisandrin A, applied in the field of medicine, can solve problems such as complex pathogenesis, difficulty in obtaining satisfactory therapeutic effect of drugs, and toxic and side effects

Active Publication Date: 2011-09-14
SHENYANG PHARMA UNIVERSITY
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the many pathogenic factors and complex pathogenesis of Alzheimer's disease, which involves abnormal pathology involving multiple systems and multiple targets, it is generally difficult to achieve satisfactory therapeutic effects with drugs with a single point of action, and there are still many synthetic drugs in use. different side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of schizandrol A, schizandrin and schizandrol extract to prevention and treatment of senile dementia
  • New application of schizandrol A, schizandrin and schizandrol extract to prevention and treatment of senile dementia
  • New application of schizandrol A, schizandrin and schizandrol extract to prevention and treatment of senile dementia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] 1. Experimental animals and materials

[0020] 1. Experimental animals

[0021] Kunming mice, male, 18-22g, 120. Provided by Beijing Huafukang Biotechnology Co., Ltd. License number: SCXK-(Beijing) 2009-0004.

[0022] 2. Drugs and reagents

[0023] Schisandrin extract (total lignan content 24%), schisandrin A (purity>95%), schisandrin A (purity>95%) are all self-made in our laboratory, dissolved in CMC-Na; Aβ 1-42 : Sigma USA, batch number: 079K8729; donepezil hydrochloride: Eisai (China) Pharmaceutical Co., Ltd., batch number: 090922A; Coomassie brilliant blue protein kit: Nanjing Jiancheng Bioengineering Institute, batch number 20101103; SOD kit: Nanjing Jiancheng Bioengineering Institute, batch number 20101103; MDA kit: Nanjing Jiancheng Bioengineering Research Institute, batch number 20101103; GSH-PX: Nanjing Jiancheng Bioengineering Research Institute, batch number 20101103; GGSG: Nanjing Jiancheng Bioengineering Research Institute, batch number: 21101110; GSH:...

Embodiment 2

[0058] 1. Instruments, materials and reagents

[0059] Cells: N9 microglia. Reagents: Fetal bovine serum (Gibco BRL, Grand Island, USA); IMDM medium (Gibco BRL, Grand Island, USA); LPS(E5:055) (Sigma, St.Louis, MO, USA); MTT (Sino-American Biotechnology, Beijing China); Minocycline (Sigma, St. Louis, MO, USA). Schizandrin A (purity>95%), self-made in this laboratory. Prepare a 100mM stock solution in DMSO and store in the dark at -20°C. Before use, dilute to the corresponding concentration with 1% serum IMDM culture medium for experiment. When the sample configured with DMSO was tested, the final concentration of DMSO was 1 ‰.

[0060] 2. Activity screening method

[0061]1. Cell culture All glassware and metal instruments (culture bottles, pipettes, solution bottles, etc.) used in cell culture and model establishment were autoclaved at 121°C for 30 min to completely remove contaminated LPS. Based on IMDM medium, a cell culture solution containing 5% calf serum, 100 U / mL...

Embodiment 3

[0077] Schisandra fruit 1 Kg, pulverized, added 8 L of water to reflux to extract twice, each time kept in a slightly boiling state for 1.5 hours, filtered, and the combined filtrate was discarded. After the residue was dried, add 5 L of 80% ethanol, heat and reflux for extraction three times, each time for 2 hours, filter, combine the filtrates and recover ethanol under reduced pressure to obtain 164 g of alcohol extract. The total lignan content is 24%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicaments and discloses application of schizandrol A, schizandrin and a schizandrol extract to prevention and treatment of senile dementia. The invention particularly relates to the effect of the schizandrol extract, the schizandrol A and the schizandrin of improving learning memory disorder of dementia mice induced by injecting Abeta1-42 into lateral ventricle and discusses the action mechanism. The result shows that the schizandrol extract, the schizandrol A and the schizandrin can obviously improve working memory disorder and spatial discrimination learning memory disorder of the mice, can improve SOD and GSH-Px activity, reduce MDA content, can increase GSH content and can reduce GGSG content, and shows that the schizandrol extract, the schizandrol A and the schizandrin can eliminate free radicals generated by in vivo oxidation stress through various routes, can inhibit lipid peroxidation and can improve oxidation resistance of an organism so as to improve oxidative stress damage caused by Abeta1-42. The schizandrol extract, the schizandrol A and the schizandrin can be applied to preparing medicaments or health-care food for preventing and treating senile dementia.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to the application of schisandrin A, schisandrin and schisandra alcohol extract for preventing and treating senile dementia. Background technique [0002] Alzheimer's Disease (AD) is the most common disease in senile dementia, which is a progressive fatal neurodegenerative disease. The clinical manifestations are characterized by progressive and degenerative brain cognition and recognition dysfunction, memory loss accompanied by changes in personality and behavior, and self-care ability gradually decreases with the development of the disease until it is completely lost. As my country enters an aging society, the incidence of Alzheimer's disease is also increasing year by year. According to the 167 million elderly population over 60 years old in my country, and the incidence rate is about 4%-6%, it is conservatively estimated that the number of sick people in my country has exceeded ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/09A61K36/57A61P25/28A23L1/29A23L33/00
Inventor 殷军胡荻杨静玉韩娜刘志惠
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com